A Phase IIB Pilot Study to Confirm the Feasibility and Tolerability of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2018
Price : $35 *
At a glance
- Drugs Beperminogene perplasmid (Primary)
- Indications Peripheral ischaemia
- Focus Adverse reactions
- Sponsors AnGes MG
- 25 Jun 2018 Status changed from active, no longer recruiting to completed.
- 20 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 20 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.